Flex Pharma
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
250 Royall St, Canton, Massachusetts, 02...Phone Number
(617) 874-1821Website
www.flex-pharma.comRevenue
<$5 MillionStock Symbol
FLKSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Flex Pharma
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis. The company also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. It markets and sells its HOTSHOT product online through its e-commerce Website, as well as through third-party Websites. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston,...Explore more
Flex Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Flex Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Flex Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Flex Pharma has new funding data
Flex Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Flex Pharma is spiking on competitors!
Earning: See what the market has to say on Flex Pharma recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Flex Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Flex Pharma
Click to see if Flex Pharma had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Flex Pharma
Find more new buyers
Compare Similar Companies to Flex Pharma
Compare insights from companies similar to Flex Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Flex Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Flex Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Flex Pharma.
Flex Pharma financials insights
Gather financial insights about Flex Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$86.4M
Flex Pharma Tech Stack
A closer look at the technologies used by Flex Pharma
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Earnings
Flex Pharma has reported revenues of $0.11 million for Q1 FY2019.
Earnings
Earnings
Flex Pharma has reported revenues of $0.16 million for the period ending on 12/31/2018.
Earnings
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Earnings
Earnings
Flex Pharma News & Media
Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference
HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference (NobleCon 16) being held February 16-18, 2020 in Hollywood, FL.Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced today that its chief executive officer, David Arthur, will present at the BIO CEO & Investor Conference being held February 10-11, 2020 in New York City.Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical StudySalarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020 Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Flex Pharma
Sign Up For FreeTo access detailed company insights
Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company operates through two segments, Consumer Operations and Drug Development. Its lead drug candidate includes FLX-7... Read More
